Charcot–Marie–Tooth disease (CMT) refers to a group of inherited neuropathies with a broad range of phenotypes, inheritance patterns and causative genes. The number of disease genes identified in CMT has expanded rapidly over the past few decades, such that more than 60 CMT-associated genes have now been discovered. This rise in genetic discovery can be attributed to the development of next-generation sequencing (NGS) technology, which allows the entire exome or genome to be sequenced in a matter of days. In this Review, we discuss how NGS is being employed in the diagnostic evaluation of patients with CMT and how the genetic advances in CMT are influencing clinical practice. In particular, we explore how genetic advances have broadened the phenotype of CMT and related disorders and how NGS allows a large number of CMT genes to be screened simultaneously early in the evaluation of an unexplained neuropathy. Finally, we discuss the different methods of NGS that can be used in CMT and related disorders, and propose a simple diagnostic algorithm in which clinical assessment and neurophysiology are used to guide the application of phenotype specific 'panels'.
Charcot–Marie–Tooth disease (CMT) should be considered as a differential diagnosis in an increasingly wide range of neuropathy phenotypes
In patients with autosomal dominant or sporadic demyelinating genetic neuropathy, screening for the chromosome 17p duplication should be performed first, before proceeding to a disease-specific panel
Disease-specific next-generation sequencing in which all known disease-causing genes are sequenced in parallel (disease-specific panels) is now the most efficient method of genetic testing in CMT
Incomplete coverage of whole-exome sequencing and whole-genome sequencing mean that their use is mainly restricted to research-led discovery of new genes
Genetic testing for appropriate CMT mutations should be considered in treatment-resistant inflammatory demyelinating neuropathies
Subscribe to Journal
Get full journal access for 1 year
only $4.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Reilly, M. M., Murphy, S. M. & Laura, M. Charcot–Marie–Tooth disease. J. Peripher. Nerv. Syst. 16, 1–14 (2011).
Ouvrier, R. What can we learn from the history of Charcot–Marie–Tooth disease? Dev. Med. Child. Neurol. 52, 405–406 (2010).
Davis, C. J., Bradley, W. G. & Madrid, R. The peroneal muscular atrophy syndrome: clinical, genetic, electrophysiological and nerve biopsy studies. I. Clinical, genetic and electrophysiological findings and classification. J. Genet. Hum. 26, 311–349 (1978).
Houlden, H. et al. Mutations in the HSP27 (HSPB1) gene cause dominant, recessive, and sporadic distal HMN/CMT type 2. Neurology 71, 1660–1668 (2008).
Raeymaekers, P. et al. Duplication in chromosome 17p11.2 in Charcot–Marie–Tooth neuropathy type 1a (CMT 1a). The HMSN Collaborative Research Group. Neuromuscul. Disord. 1, 93–97 (1991).
Murphy, S. M. et al. Charcot–Marie–Tooth disease: frequency of genetic subtypes and guidelines for genetic testing. J. Neurol. Neurosurg. Psychiatry 83, 706–710 (2012).
Cottenie, E. et al. Rapidly progressive asymmetrical weakness in Charcot–Marie–Tooth disease type 4J resembles chronic inflammatory demyelinating polyneuropathy. Neuromuscul. Disord. 23, 399–403 (2013).
Houlden, H. et al. The phenotype of Charcot–Marie–Tooth disease type 4C due to SH3TC2 mutations and possible predisposition to an inflammatory neuropathy. Neuromuscul. Disord. 19, 264–269 (2009).
Michell, A. W. et al. GJB1 gene mutations in suspected inflammatory demyelinating neuropathies not responding to treatment. J. Neurol. Neurosurg. Psychiatry 80, 699–700 (2009).
Houlden, H. et al. Clinical, pathological and genetic characterization of hereditary sensory and autonomic neuropathy type 1 (HSAN I). Brain 129, 411–425 (2006).
Saporta, A. S. et al. Charcot–Marie–Tooth disease subtypes and genetic testing strategies. Ann. Neurol. 69, 22–33 (2011).
Schouten, J. P. et al. Relative quantification of 40 nucleic acid sequences by multiplex ligation-dependent probe amplification. Nucleic Acids Res. 30, e57 (2002).
Rehm, H. L. Disease-targeted sequencing: a cornerstone in the clinic. Nat. Rev. Genet. 14, 295–300 (2013).
Lupski, J. R. et al. Whole-genome sequencing in a patient with Charcot–Marie–Tooth neuropathy. N. Engl. J. Med. 362, 1181–1191 (2010).
Landoure, G. et al. Exome sequencing identifies a novel TRPV4 mutation in a CMT2C family. Neurology 79, 192–194 (2012).
NHLBI Exome Sequencing Project (ESP). Exome Variant Server [online].
Pitceathly, R. D. et al. Genetic dysfunction of MT-ATP6 causes axonal Charcot–Marie–Tooth disease. Neurology 79, 1145–1154 (2012).
Chaudhry, R. et al. Re-analysis of an original CMTX3 family using exome sequencing identifies a known BSCL2 mutation. Muscle Nerve 47, 922–924 (2013).
Liao, J. P. & Waclawik, A. J. Nerve root hypertrophy in CMT type 1A. Neurology 62, 783 (2004).
Ishigami, N., Kondo, M. & Nakagawa, M. Case of Charcot–Marie–Tooth disease type 1A with increased cerebrospinal fluid proteins and nerve root hypertrophy [Japanese]. Rinsho Shinkeigaku 48, 419–421 (2008).
d'Ydewalle, C. et al. HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot–Marie–Tooth disease. Nat. Med. 17, 968–974 (2011).
Patzko, A. et al. Curcumin derivatives promote Schwann cell differentiation and improve neuropathy in R98C CMT1B mice. Brain 135, 3551–3566 (2012).
Sereda, M. W., Meyer zu Horste, G., Suter, U., Uzma, N. & Nave, K. A. Therapeutic administration of progesterone antagonist in a model of Charcot–Marie–Tooth disease (CMT-1A). Nat. Med. 9, 1533–1537 (2003).
Garofalo, K. et al. Oral L-serine supplementation reduces production of neurotoxic deoxysphingolipids in mice and humans with hereditary sensory autonomic neuropathy type 1. J. Clin. Invest. 121, 4735–4745 (2011).
Passage, E. et al. Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot–Marie–Tooth disease. Nat. Med. 10, 396–401 (2004).
Burns, J. et al. Ascorbic acid for Charcot–Marie–Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial. Lancet Neurol. 8, 537–544 (2009).
Micallef, J. et al. Effect of ascorbic acid in patients with Charcot–Marie–Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 8, 1103–1110 (2009).
Pareyson, D. et al. Ascorbic acid in Charcot–Marie–Tooth disease type 1A (CMT-TRIAAL and CMT-TRAUK): a double-blind randomised trial. Lancet Neurol. 10, 320–328 (2011).
Singer, M. A., Vernino, S. A. & Wolfe, G. I. Idiopathic neuropathy: new paradigms, new promise. J. Peripher. Nerv. Syst. 17 (Suppl. 2), 43–49 (2012).
Klein, C. J. et al. Mutations in DNMT1 cause hereditary sensory neuropathy with dementia and hearing loss. Nat. Genet. 43, 595–600 (2011).
MacLeod, R. et al. Recommendations for the predictive genetic test in Huntington's disease. Clin. Genet. 83, 221–231 (2013).
Davidson, G. et al. Frequency of mutations in the genes associated with hereditary sensory and autonomic neuropathy in a UK cohort. J. Neurol. 259, 1673–1685 (2012).
A. M. Rossor is funded by the National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712), and an IPSEN clinical research fellowship. M. M. Reilly is funded by a Medical Research Council grant (G0601943), and by the National Institutes of Neurological Diseases and Stroke and office of Rare Diseases (U54NS065712). Work undertaken at University College London Hospitals/University College London was partly funded by the Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme.
The authors declare no competing financial interests.
About this article
Cite this article
Rossor, A., Polke, J., Houlden, H. et al. Clinical implications of genetic advances in Charcot–Marie–Tooth disease. Nat Rev Neurol 9, 562–571 (2013). https://doi.org/10.1038/nrneurol.2013.179
Pediatric Nephrology (2021)
Biochemistry (Moscow) (2021)
Annals of Clinical and Translational Neurology (2021)
Neuroscience Letters (2021)
A weakened interface in the P182L variant of HSP27 associated with severe Charcot‐Marie‐Tooth neuropathy causes aberrant binding to interacting proteins
The EMBO Journal (2021)